Semaglutide is the active ingredient
It displays substantial weight loss while improving metabolic health markers
For this purpose, the researchers conducted a systematic literature search in PubMed, Web of Science, and Scopus until October 2022
These steps help reduce side effects and improve comfort during GLP-1 therapy
Liraglutide has also been found to reduce food obsessions, overeating, aggression, and other repetitive behaviors in a patient with autism spectrum disorder, intellectual disability, and obsessive eating disorder
Most notably, a series of large-scale cardiovascular outcome trials (CVOTs) created robust clinical evidence for the cardiovascular benefits of GLP-1RAs in patients with T2DM and high cardiovascular risk or established atherosclerotic cardiovascular disease (ASCVD) [1, 2]